

CEPI – Coalition for Epidemic Preparedness Innovations

Stopping future epidemics
by developing new vaccines

www.cepi.net



NORWEGIAN
GOVERNMENT



The
Federal Government



JAPAN GOV
THE GOVERNMENT OF JAPAN



DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology

CEPI

BILL & MELINDA
GATES foundation



WORLD
ECONOMIC
FORUM


World Economic Forum, Davos 19 Jan





Foto: Daniel Berehulak, The New York Times

Testing of Ebola vaccines – a successful but unfinished story



The start: A need for global solutions


ADVANCE UNEDITED COPY

Protecting Humanity from Future Health Crises

Report of the
High-level Panel on the Global Response to Health Crises

25 January 2016

Report of the Ebola Interim Assessment Panel



AN R&D BLUEPRINT FOR ACTION TO PREVENT EPIDEMICS PLAN OF ACTION MAY 2016



Outcome document
Financing of R&D Preparedness and Response to Epidemic
Emergencies
October 29-30, 2015
Oslo, Norway

Background

This Outcome document summarizes discussions that took place during the Oslo consultation on *Financing of R&D Preparedness and Response to Epidemic Emergencies* (October 29-30, 2015). It reflects views expressed and the discussion that took place, but does not necessarily reflect all interventions. Names of representatives of countries and organizations participating in the Oslo consultation on Financing can be found on the webpage of the Norwegian Institute of Public Health. Stakeholders represented included government, industry, NGOs and academia as well as charitable foundations and other relevant actors. The consultation was jointly organized by WHO and the Norwegian Institute of Public Health and hosted by the Norwegian Institute of Public Health.

THE LANCET

Online First Current Issue All Issues Special Issues Multimedia Information for Authors

All Content Search Advanced Search

Access provided by The Wellcome Trust

< Previous Article Volume 386, No. 10009, p2204-2221, 28 November 2015 Next Article >

Health Policy

Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola

Dr Suerie Moon, PhD, DPhil, Sophie Delaunay, M.D., Prof Eric Goosby, MD, Prof Leung, MD, J Stephen Morris, Benjamin Hawkins, PhD, L...
Published Online: 22 November 2015

NATIONAL ACADEMY OF MEDICINE

ABOUT THE NAM PROGRAMS INITIATIVES PERSPECTIVES NEWS SUPPORT MEMBER RESOURCES

Global Health Risk Framework

The Neglected Dimension of Global Security: A Framework to Counter Infectious Disease Crises

Download the Report

The NEW ENGLAND JOURNAL of MEDICINE

HOME ARTICLES & MULTIMEDIA ISSUES SPECIALTIES & TOPICS FOR AUTHORS CME

Perspective

Establishing a Global Vaccine-Development Fund

Stanley A. Plotkin, M.D., Adel A.F. Mahmoud, M.D., Ph.D., and Jeremy Farrar, M.D., Ph.D.
N Engl J Med 2015; 373:297-300 | July 23, 2015 | DOI: 10.1056/NEJMp1509620

Comments open through July 29, 2015

Article References Citing Articles (8) Comments (2) Metrics


What is CEPI?

- CEPI is a partnership of public, private, philanthropic and civil society organisations
- CEPI will *stimulate, finance and coordinate* vaccine development
 - against priority threats,
 - particularly when development is unlikely to occur through market incentives alone.

How will CEPI work?

- CEPI will move specific targeted vaccine candidates through late preclinical studies to proof of concept and safety in humans before epidemics begin
 - larger effectiveness trials can begin swiftly in an outbreak
 - small stockpiles are ready for potential emergency use
- CEPI will build technical platforms and institutional capacities that can be rapidly deployed against new and unknown pathogens

CEPI's end-to-end gap-filling role: a sustainable partnership approach



Phase	1 Discovery	2 Development/Licensure	3 Manufacturing	4 Delivery/Stockpiling
Current Stakeholders	<ul style="list-style-type: none"> • Academia • Governments • WT/NIH • EC/IMI • GLOPID-R • Industry • Regulators • Biotech 	<ul style="list-style-type: none"> • Industry • Governments • Regulators • WT/NIH • EC/IMI • Bill and Melinda Gates Foundation • BARDA/DTRA etc. • WHO • Biotech • PDPs 	<ul style="list-style-type: none"> • Industry • BARDA • CMOs • Regulators • Governments • WHO • GHIF 	<ul style="list-style-type: none"> • GAVI • UNICEF • PAHO • Governments • WHO • Industry • Pandemic Emergency Facility (World Bank) • WHO Contingency Fund

Strategic objectives

1

Preparedness

2

Response speed

3

Predictability

4

Equity

CEPI's operating principles conceptualized in Business Plan

- Adhering to equitable access principles of affordable pricing and availability of vaccines by priority populations in emergencies
- Securing industry participation through predictable pathways and risk/benefit sharing arrangements and handling of liability through indemnification
- Supporting data sharing and sample sharing mechanisms, and long-term development of regional capabilities for epidemic vaccine preparedness

CEPI's 3 Prioritized Diseases

Lassa

MERS

Nipah

Starting point: WHO's list of priority pathogens against which medical countermeasures are urgently needed from the WHO R&D Blueprint process.

CEPI's SAC chose the three diseases based on a set of criteria including

- public health impact
- risk of an outbreak occurring
- feasibility of vaccine development

CEPI's Calls for Proposals for Vaccine Development

1. MERS, Lassa-fever and Nipah virus.
Step 1: Deadline 8 March
Step 2: 24 May

2. Filo-viruses (Ebola, Marburg)
Planned launch June

3. Vaccine platform technology
Planned launch Oct/Nov 2017

Regulatory science meeting - challenges in understanding vaccine based protection against Ebola

Date: 22 March 2017

Place: Washington DC, National Academy of Sciences

Type of meeting: By invitation

Organisers: CEPI, with active participation of FDA, EMA, BARDA and WHO (and potentially EC)

To clarify current gaps in scientific knowledge that makes it challenging to use non-traditional regulatory pathways for the approval of Ebola vaccines in the absence of clinical efficacy data, by initiating a process to allow regulators and Ebola vaccine developers discuss what could be attempted to overcome these issues and arrive at a joint action plan.

CEPI-INSERM Scientific Conference

Vaccines against Emerging Infections - a Global Insurance

Introducing CEPI Partners Forum

21-22 February 2017

Institut Imagine, Paris



CEPI's First Investors

Investor	Amount
Japan	\$125,000,000
Norway	\$120,000,000
Germany	\$95,000,000
Bill&Melinda Gates Foundation	\$100,000,000
Wellcome Trust	\$100,000,000
In addition: EC plan to co-fund with €250 mill	

A young girl with a joyful expression is holding a white sign with black text. She is wearing a pink t-shirt. The background shows a clothesline with various items of clothing hanging on it, set against a backdrop of green foliage and a brick wall. The scene is outdoors, likely in a residential area.

“THANK
YOU
SCIENCE!”